The deal represents an expansion of Boehringer Ingelheim’s investments in the CLD treatment space and scales Ochre Bio’s ambitions, specifically around MASH cirrhosis.
Sagimet’s liver drug impresses in year-long NASH trial
The pill from Sagimet Biosciences led to a statistically significant treatment effect in patients with NASH and moderate-to-severe liver fibrosis at the 52-week mark, data show.
Connecting the dots: Salix’s campaign educates patients on link between liver disease, OHE